-
Mashup Score: 0Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient Setting - 1 year(s) ago
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Siltuximab May Be Effective Treatment for CRS/ICANS Following CAR T-Cell Therapy #CARTcelltherapy #CRS #ICANS #Oncology #Nursing #Tandem23 @ASTCT https://t.co/bBcH5w01nf
-
-
Mashup Score: 0Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review - 1 year(s) ago
Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today. The decision applies to phase 1/phase 2 trials designed to evaluate the safety and preliminary efficacy of the company’s GoCAR-T cell product candidates — BPX-601 and BPX-603 — in combination with the small molecule inhibitor
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review. https://t.co/P3dPIsoBOT @BellicumPharma #carTcelltherapy #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient Setting - 1 year(s) ago
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients. #tandem23 #oncology #nursing #CARtcelltherapy @ASTCT https://t.co/4ZUXoshm8S
-
-
Mashup Score: 0
At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR T-cell therapy has the potential to be transferred to the outpatient setting, according to Jennifer Peterson, MS, RN, OCN, BMTCN. #CARTcelltherapy #oncology #Nursing #Tandem23 @cityofhope Link: https://t.co/YllgjkLZsf https://t.co/NmtHQzZ2AP
-
-
Mashup Score: 0Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient Setting - 1 year(s) ago
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient Setting #tandem23 #oncology #nursing #CARtcelltherapy @ASTCT https://t.co/MG7kTgR21E
-
-
Mashup Score: 0
At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program. #CARTcelltherapy #oncology #Nursing #Tandem23 @cityofhope Link: https://t.co/x6V6DBzXOs https://t.co/qZe4aAKF5S
-
-
Mashup Score: 0Ide-Cel Leads to Extended Survival, Increased Response Rates in R/R Multiple Myeloma - 1 year(s) ago
Patients with relapsed or refractory multiple myeloma experienced improved progression-free survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with relapsed/refractory multiple myeloma who received ide-cel experienced a significant survival benefit with an improved response rate compared with those treated with standard regimens #mmsm #oncology #nursing #CARTcelltherapy https://t.co/qNK4GF7as4
-
-
Mashup Score: 0
At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Moving CAR T-Cell Treatment to Outpatient Setting: A Real-World Case Study #CARTcelltherapy #oncology #Nursing #Tandem23 @cityofhope https://t.co/pkweGcVlx4
-
-
Mashup Score: 0Ide-Cel Leads to Extended Survival, Increased Response Rates in R/R Multiple Myeloma - 1 year(s) ago
Patients with relapsed or refractory multiple myeloma experienced improved progression-free and overall survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with relapsed or refractory multiple myeloma experienced improved progression-free and overall survival with ide-cel. CRS rates were high with this treatment. #multiplemyeloma #mmsm #oncology #nursing #CARTcelltherapy @NEJM @ClinicaNavarra https://t.co/IyG4vVC8Lf
-
Remote patient monitoring (RPM) may serve as an effective tool in allowing patients to safely receive CAR T-cell therapy in the outpatient setting #tandem23 #oncology #nursing #CARtcelltherapy @ASTCT link: https://t.co/orchBdNgdB https://t.co/NSA6G0wF5I